ETTX - エンタシス・セラピュ―ティクス (Entasis Therapeutics Holdings Inc.)

ETTXのニュース

   Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript  2021/11/06 19:50:08 Seeking Alpha
   Entasis Therapeutics EPS beats by $0.02  2021/11/04 11:45:17 Seeking Alpha
   Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update  2021/11/04 11:30:00 Intrado Digital Media
Management to host a conference call on November 4, 2021 at 8:00am ET Management to host a conference call on November 4, 2021 at 8:00am ET
   Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021  2021/10/28 12:00:00 Intrado Digital Media
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow managements prepared remarks.
   At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting  2021/10/23 14:30:00 Stocks Register
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) concluded the trading at $2.64 on Friday, October 22 with a fall of -5.71% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.80 and 5Y monthly beta was reading 1.72 with its price kept floating in At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting Read More »
   Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021  2021/10/28 12:00:00 Intrado Digital Media
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow managements prepared remarks.
   At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting  2021/10/23 14:30:00 Stocks Register
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) concluded the trading at $2.64 on Friday, October 22 with a fall of -5.71% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.80 and 5Y monthly beta was reading 1.72 with its price kept floating in At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting Read More »
   Entasis Therapeutics (NASDAQ:ETTX) Price Target Increased to $7.00 by Analysts at BMO Capital Markets  2021/10/23 10:26:57 Dakota Financial News
Entasis Therapeutics (NASDAQ:ETTX) had its price objective increased by BMO Capital Markets from $5.00 to $7.00 in a research note released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock. Several other analysts have also issued reports on ETTX. Zacks Investment Research upgraded shares of Entasis Therapeutics from a sell rating []
   Entasis Therapeutics (NASDAQ:ETTX) Given New $6.00 Price Target at HC Wainwright  2021/10/23 06:44:41 Transcript Daily
Entasis Therapeutics (NASDAQ:ETTX) had its price target raised by HC Wainwright from $5.00 to $6.00 in a report released on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. ETTX has been the subject of several other research reports. Zacks Investment Research upgraded shares of Entasis Therapeutics from a sell []
   FY2022 Earnings Forecast for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Issued By Wedbush  2021/10/22 07:40:41 Dakota Financial News
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Analysts at Wedbush reduced their FY2022 earnings estimates for shares of Entasis Therapeutics in a research note issued to investors on Tuesday, October 19th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.87) for the year, down from their previous estimate of []
   Entasis Therapeutics introduces ETX0462 targeting gram-negative and biothreat pathogens  2021/07/01 12:14:29 Seeking Alpha
   Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens  2021/07/01 12:00:00 Intrado Digital Media
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.
   Entasis Therapeutics shares rise after lining up ETX0462 poster presentation  2021/06/18 12:10:51 Seeking Alpha
   Entasis Therapeutics Holdings Inc. Shares Close the Week 20.2% Higher - Weekly Wrap  2021/03/12 22:30:00 Kwhen Finance
Entasis Therapeutics Holdings Inc. shares closed this week 20.2% higher than it did at the end of last week. The stock is currently up 23.1% year-to-date, up 12.6% over the past 12 months, and down 71.5% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $3.14 and as low as $2.54 this week.Shares closed 5e+1% below its 52-week high and 9e+1% above its 52-week low.Trading volume this week was 16.3% higher than the 10-day average and 6.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 137.8% The company's stock price performance over the past 12 months beats the peer average by 9.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Entasis Therapeutics Holdings Inc. Shares Close the Week 21.1% Lower - Weekly Wrap  2021/02/26 22:30:00 Kwhen Finance
Entasis Therapeutics Holdings Inc. shares closed this week 21.1% lower than it did at the end of last week. The stock is currently up 7.7% year-to-date, down 48.4% over the past 12 months, and down 75.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.5%. Trading Activity Shares traded as high as $3.34 and as low as $2.57 this week.Shares closed 5e+1% below its 52-week high and 7e+1% above its 52-week low.Trading volume this week was 3.3% lower than the 10-day average and 14.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.5% The company's stock price performance over the past 12 months lags the peer average by -638.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

calendar